MedPath

Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto

Conditions
Thalassemia
Fertility
Pregnancy
Registration Number
NCT00327639
Lead Sponsor
University Health Network, Toronto
Brief Summary

Treatment of patients with beta thalassemia in North America has altered dramatically during the past 40 years, with improvements in transfusion therapy and introduction of iron chelation therapy. Thalassemia patients now enjoy an increased life expectancy to the fifth and sixth decades of life, with fertility and childbearing becoming important issues. Data regarding this important topic remain limited, without clear data regarding iron control including serial assessment of hepatic iron concentration, the need for assistance in becoming pregnant, and use of iron chelating agents during pregnancy. As the life expectancy increases and overall health improves in thalassemia, clear data on fertility, pregnancy complications, and the effect of pregnancy on maternal health in thalassemia patients are necessary since these will have a direct impact on patient care, quality of life, and patient expectations.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Thalassemia, thalassemia intermedia or E-thalassemia patients in Toronto
  • Subject has attempted conception
Read More
Exclusion Criteria
  • Subject has any other form of blood disease
  • Subject has not attempted conception
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Health Network, Toronto General Hospital

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath